Abstract
Background and Aims : At the core of atherosclerosis lies a process of chronic inflammation. With new anti-inflammatory therapeutics entering the field of research, accurate surrogate markers to evaluate their effectiveness in reducing cardiovascular events are paramount. 68Ga-DOTATATE has recently been proposed as a more specific marker of arterial wall inflammation than the metabolic marker 18F-fluorodeoxyglucose (18F-FDG). Here, we set out to investigate whether 68Ga-DOTATATE uptake is amenable to therapeutic intervention in patients with diabetes mellitus type 2 (DM2).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
